close-icon

Log In to Bolder Science

Don't have an account? Sign Up

close-icon

Please enter your email address.

You will receive a link to create a new password via email.

Log In

close-icon

Create an Account

  • 8 characters minimum
  • First character may not be a number
  • Last character may not be a number

By completing and submitting this form, you agree to allow Bolder Science to collect the information provided and to receive communications from Bolder Science in the future regarding disease education and research updates.

close-icon

Welcome and thank you for creating an account!

At Bolder Science, we want your clinical trial search experience to be the best it can be. Complete the following prompts to easily find the trials you are interested in and see trials recruiting near you. You can adjust these selections in your dashboard after creating your account.

Condition Categories

Condition categories are pulled directly from ClinicalTrials.gov. Choose 1 or more condition categories that you are interested in:

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

Set a default location

Back
Filter 230 trials Clear all
Filter by:

IPD in RRMM Characterized With Genomic Abnormalities of Adverse Prognostic

  • Status Not yet recruiting
    Not yet recruiting
  • Condition Multiple Myeloma, Relapsed and Refractory Multiple Myeloma, Genet...
    Multiple Myeloma, Relapsed and Refractory Multiple Myeloma, Genet...
  • Phase Phase 2
    Phase 2
INTERVENTION

Drug: Ixazomib/Pomalidomide/Dexamethasone

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: Ixazomib/Pomalidomide/Dexamethasone

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Brief Summary

This study is a Multicenter, Open-label, Phase II study of ixazomib, plus Pomalidomide and Dexamethasone regimen (IPD) in RRMM with adverse Genomic Abnormalities.

Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Multiple Myeloma
    Multiple Myeloma
  • Phase Phase 2
    Phase 2
INTERVENTION

Drug: POM, Drug: Steroids, Drug: PLD, Drug: CFZ, Drug: BTZ, Drug: CLA, Drug: CY

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: POM, Drug: Steroids, Drug: PLD, Drug: CFZ, Drug: BTZ, Drug: CLA, Drug: CY

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

California Cancer Associates for Research & Excellence (cCARE), Encinitas, California, United States

Brief Summary

The purpose of this clinical research study is to evaluate the safety and effectiveness (good and bad effects) of pomalidomide given as part of a combination therapy that include more than just steroids to treat subjects with relapsed (subjects whose disease came back) or refractory (subjects whose disease did not respond to past treatment) multiple myeloma (MM). Pomalidomide (alone or in combination with dexamethasone) has been approved by the United States Food and Drug Administration (FDA) for the treatment of MM patients who have received at least two prior therapies, including lenalidomide and bortezomib, and have demonstrated disease progression on or within 60 days of completion of their last therapy. However, the use of pomalidomide in combination with other drugs used to treat MM, such as chemotherapeutic agents and proteasome inhibitors, is currently being tested and is not approved. Pomalidomide is in the same drug class as thalidomide and lenalidomide. Like lenalidomide, pomalidomide is a drug that alters the immune system and it may also interfere with the development of small blood vessels that help support tumor growth. Therefore, in theory, it may reduce or prevent the growth of cancer cells. The testing done with pomalidomide thus far has shown that it is well-tolerated and effective for subjects with MM both on its own and in combination with dexamethasone. Using another drug class, namely proteasome inhibitors, we have demonstrated that simply replacing a proteasome inhibitor with another in an established anti-myeloma treatment regimen can frequently overcome resistance regardless of the other agents that are part of the anti-myeloma regimen. Importantly, the toxicity profile of the new combinations closely resembled that of the proteasome inhibitor administered as a single agent. Based on this experience, we hypothesize that the replacement of lenalidomide with pomalidomide will yield similar results in a similar relapsed/refractory MM patient population.

Nivolumab, Ixazomib, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Myeloma

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Relapsed Multiple Myeloma, Refractory Multiple Myeloma
    Relapsed Multiple Myeloma, Refractory Multiple Myeloma
  • Phase Phase 2
    Phase 2
INTERVENTION

Drug: Nivolumab, Drug: Ixazomib, Drug: Dexamethasone, Drug: Cyclophosphamide

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: Nivolumab, Drug: Ixazomib, Drug: Dexamethasone, Drug: Cyclophosphamide

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States

Brief Summary

This research is being done to assess the effectiveness and safety of the combination of nivolumab with ixazomib, cyclophosphamide, and dexamethasone in relapsed and refractory multiple myeloma.

A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Multiple Myeloma
    Multiple Myeloma
  • Phase Phase 2
    Phase 2
INTERVENTION

Drug: Elotuzumab, Drug: Pomalidomide, Drug: Bortezomib, Drug: Dexamethasone

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: Elotuzumab, Drug: Pomalidomide, Drug: Bortezomib, Drug: Dexamethasone

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States

Brief Summary

This research study is studying a combination of study drugs as a possible treatment for relapsed and refractory Multiple Myeloma. The interventions involved in this study are elotuzumab, pomalidomide, bortezomib, dexamethasone.

A Study to Desensitize Allergic Reactions to Treatments for Blood Disorders

  • Status Recruiting
    Recruiting
  • Condition Amyloidosis, Multiple Myeloma
    Amyloidosis, Multiple Myeloma
  • Phase Phase 2
    Phase 2
INTERVENTION

Drug: Lenalidomide, Drug: Pomalidomide

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: Lenalidomide, Drug: Pomalidomide

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Princess Margaret Cancer Centre, Toronto, Ontario, Canada

Brief Summary

Patients with multiple myeloma (a type of blood cancer affecting the white blood cells) or amyloidosis (abnormal buildup of a protein called amyloid in the body) are often given treatment with the drugs lenalidomide or pomalidomide. Some patients may experience an allergic reaction to these drugs which would mean stopping the treatment. The purpose of this research study is to see how safe and useful desensitization is in allowing patients to receive further treatment with lenalidomide or pomalidomide.

Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL

  • Status Recruiting
    Recruiting
  • Condition Multiple Myeloma, Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymp...
    Multiple Myeloma, Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymp...
  • Phase Phase 1
    Phase 1
INTERVENTION

Biological: Nicotinamide Expanded Haploidentical or Mismatched Related Donor Natural Killer Cells

Eligibility
  • Ages: 18 to 70 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: Yes
INTERVENTION

Biological: Nicotinamide Expanded Haploidentical or Mismatched Related Donor Natural Killer Cells

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States

Brief Summary

This is a phase I trial with pilot expansion of HLA-haploidentical or HLA-mismatched related donor nicotinamide expanded-natural killer (NAM-NK) cell based therapy for patients with relapsed or refractory multiple myeloma (MM) or relapsed/refractory CD20-positive non-Hodgkin lymphoma (NHL). The primary endpoint of the study is to determine the maximum tolerated dose (MTD) of NAM-NK cells while maintaining safety.

Pomalidomide, Ixazomib, and Dexamethasone With or Without Intensification by Cyclophosphamide in Relapsed or Refractory Multiple Myeloma

  • Status Recruiting
    Recruiting
  • Condition Refractory Multiple Myeloma
    Refractory Multiple Myeloma
  • Phase Phase 2
    Phase 2
INTERVENTION

Drug: MLN9708, Drug: Pomalidomide 4 MG Oral Capsule, Drug: Dexamethasone, Drug: Cyclophosphamide

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: MLN9708, Drug: Pomalidomide 4 MG Oral Capsule, Drug: Dexamethasone, Drug: Cyclophosphamide

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Klinikum rechts der Isar der TU München / III. Med. Klinik und Poliklinik, Munich, Bayern, Germany

Brief Summary

The study is designed as a multicenter, non-randomized, Phase II trial with one treatment arm. A total of 82 patients of both genders and older than 18 years with relapsed/refractory multiple myeloma are planned to be included in the study. After the first 6 patients will have finished the first treatment cycle of the induction phase the DMC will assess safety and tolerability of the treatment schedule and decide about the further continuation of the study.

Phase 1b Study Evaluating OPomD in Relapsed or Refractory Multiple Myeloma

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Relapsed or Refractory Multiple Myeloma
    Relapsed or Refractory Multiple Myeloma
  • Phase Phase 1
    Phase 1
INTERVENTION

Drug: Immediate Release (IR) Formulation, Drug: Gastro-Retentive (GR) Formulation, Drug: Dexamethasone, Drug: Pomalidomide

Eligibility
  • Ages: 18 to 100 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: Immediate Release (IR) Formulation, Drug: Gastro-Retentive (GR) Formulation, Drug: Dexamethasone, Drug: Pomalidomide

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Research Site, West Hollywood, California, United States

Brief Summary

A study evaluating two new formulations of oprozomib plus pomalidomide and dexamethasone in patients with relapsed refractory multiple myeloma.

Up-front CART-BCMA With or Without huCART19 in High-risk Multiple Myeloma

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Multiple Myeloma
    Multiple Myeloma
  • Phase Phase 1
    Phase 1
INTERVENTION

Combination Product: BCMA CART + huCART19, Combination Product: CART BCMA or CART BCMA + huCART19, Combination Product: Single-dose infusion of CART BCMA or CART BCMA + huCART19, Combination Product: BCMA CART + huCART19

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Combination Product: BCMA CART + huCART19, Combination Product: CART BCMA or CART BCMA + huCART19, Combination Product: Single-dose infusion of CART BCMA or CART BCMA + huCART19, Combination Product: BCMA CART + huCART19

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Univ. of Pennsylvania, Philadelphia, Pennsylvania, United States

Brief Summary

This is an open-label phase 1 study to assess the safety and pharmacodynamics of CART-BCMA, with or without huCART19, in patients responding to first- or second-line therapy for high-risk multiple myeloma. The regimen evaluated in this study is based on established safety of CARTBCMA demonstrated in UPCC 14415/IRB#822756 at dose of 5x108 cells, administered as split infusions, following cyclophosphamide 1.5 g/m2 in patients with relapsed/refractory myeloma. This study tests CART-BCMA (1) as consolidation of early therapy for multiple myeloma, (2) with addition of fludarabine to the lymphodepleting chemotherapy regimen, (3) in combination with huCART19, and (4) as a single rather than split-dose infusion.

Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Relapsed or Refractory Multiple Myeloma
    Relapsed or Refractory Multiple Myeloma
  • Phase Phase 2
    Phase 2
INTERVENTION

Drug: Carfilzomib, Drug: Dexamethasone, Drug: Pomalidomide

Eligibility
  • Ages: 18 to 99 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: Carfilzomib, Drug: Dexamethasone, Drug: Pomalidomide

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

University of Alabama at Birmingham, Birmingham, Alabama, United States

Brief Summary

A Study Evaluating Treatment of Multiple Myeloma with Carfilzomib in Combination with Pomalidomide and Dexamethasone